Literature DB >> 23127115

The role of interleukin-9 in lymphoma.

Xiao Lv1, Xin Wang.   

Abstract

Although much progress has been made in the treatment of lymphomas, the unclear molecular etiology limits its further development. Interleukin-9 (IL-9) was initially described as a growth factor secreted by activated helper T cells type 2 (Th2). Various observations have demonstrated its diverse actions in immune and inflammatory responses. In recent years, a resurgence of interest in IL-9 has been spurred by the expanded identification of its cellular sources and biological targets. Also, the determination of its growth-proliferative and anti-apoptotic activities on multiple transformed cells implies a potential role of this cytokine in tumorigenesis. In this article we review the biologic properties and signal transduction pathways of IL-9, and furthermore discuss its possible role in lymphomagenesis as well as its impact on non-malignant infiltrating cells which are characteristic of the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23127115     DOI: 10.3109/10428194.2012.745072

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.

Authors:  Dominique B Hoelzinger; Ana Lucia Dominguez; Peter A Cohen; Sandra J Gendler
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

2.  Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.

Authors:  G Guggino; M Lo Pizzo; D Di Liberto; A Rizzo; P Cipriani; P Ruscitti; G Candore; C M Gambino; G Sireci; F Dieli; R Giacomelli; G Triolo; F Ciccia
Journal:  Clin Exp Immunol       Date:  2017-08-23       Impact factor: 4.330

3.  Overexpression of IL-9 receptor in diffuse large B-cell lymphoma.

Authors:  Xiao Lv; Lili Feng; Xiaosheng Fang; Yujie Jiang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

4.  Minimum degree of overlap between IL-9R and IL-2R on human T lymphoma cells: A quantitative CLSM and FRET analysis.

Authors:  Enikő Nizsalóczki; Péter Nagy; Gábor Mocsár; Ágnes Szabó; István Csomós; Thomas A Waldmann; György Vámosi; László Mátyus; Andrea Bodnár
Journal:  Cytometry A       Date:  2018-10-31       Impact factor: 4.355

Review 5.  TH9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer.

Authors:  Yan Li; Qing Yu; Zhengguo Zhang; Jian Wang; Simin Li; Jiangyuan Zhang; Guangwei Liu
Journal:  Oncotarget       Date:  2016-10-25

Review 6.  Novel Perspectives in Pseudomyxoma Peritonei Treatment.

Authors:  Antonio Sommariva; Marco Tonello; Giulia Rigotto; Nayana Lazzari; Pierluigi Pilati; Maria Luisa Calabrò
Journal:  Cancers (Basel)       Date:  2021-11-27       Impact factor: 6.639

7.  Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?

Authors:  Tomas Mickevicius; Alvita Vilkeviciute; Brigita Glebauskiene; Loresa Kriauciuniene; Rasa Liutkeviciene
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

8.  Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma.

Authors:  Jing Zhang; Wei-da Wang; Qi-Rong Geng; Liang Wang; Xiao-Qin Chen; Cheng-Cheng Liu; Yue Lv
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

9.  Evaluation of the T helper 17 cell specific genes and the innate lymphoid cells counts in the peripheral blood of patients with the common variable immunodeficiency.

Authors:  Mazdak Ganjalikhani-Hakemi; Reza Yazdani; Roya Sherkat; Vida Homayouni; Mohsen Masjedi; Mohsen Hosseini
Journal:  J Res Med Sci       Date:  2014-03       Impact factor: 1.852

Review 10.  Cytokine-Induced Modulation of Colorectal Cancer.

Authors:  Lukas F Mager; Marie-Hélène Wasmer; Tilman T Rau; Philippe Krebs
Journal:  Front Oncol       Date:  2016-04-19       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.